Keulen W, Boucher C, Berkhout B
Department of Virology, University of Amsterdam, The Netherlands.
Antiviral Res. 1996 Jun;31(1-2):45-57. doi: 10.1016/0166-3542(96)00944-8.
The enzyme reverse transcriptase (RT) plays a fundamental role in the replication of the human immunodeficiency virus type 1 (HIV-1) and several antiviral agents that target this key enzyme have been developed. Unfortunately, treatment of patients with RT inhibitors results in the appearance of drug-resistant variants with specific mutations in the RT protein. We hypothesized that if "difficult' resistance mutations (e.g. transversions/double-hits) are consistently observed at certain positions, it is likely that "easier' nucleotide substitutions (transitions/single-hits) at that codon do not result in a drug-resistant and/or active RT enzyme. In this study, we examined codon changes involved in RT drug resistance against nucleoside and non-nucleoside inhibitors and listed all easier substitutions, which apparently were not selected, either due to reduced enzyme RT activity or lack of drug resistance. These predictions on the requirements for resistance were confirmed by published mutational data on RT variants. We also propose that differences in mutation type can explain the order of appearance of substitutions in case multiple amino acid changes are required for optimal fitness. Differences in mutation pattern have been reported for drug-resistant HIV-1 variants selected in tissue culture compared with variants found in treated patients. In contrast to the in vivo situation, a relatively small population size is handled in in vitro tissue culture systems and this may limit the chances of creating a resistance mutation. Indeed, inspection of the codon changes indicates that the in vitro culture system is more strongly biased towards the relatively easy nucleotide substitutions. These results suggest that the nucleotide substitution pattern can provide important information on RT drug resistance.
逆转录酶(RT)在1型人类免疫缺陷病毒(HIV-1)的复制过程中发挥着重要作用,针对这一关键酶的多种抗病毒药物已被研发出来。遗憾的是,使用RT抑制剂治疗患者会导致RT蛋白出现特定突变的耐药变异体。我们推测,如果在某些位置持续观察到“难发生的”耐药突变(例如颠换/双位点突变),那么该密码子处“较易发生的”核苷酸替换(转换/单位点突变)很可能不会产生耐药性和/或活性RT酶。在本研究中,我们检测了RT对核苷类和非核苷类抑制剂耐药所涉及的密码子变化,并列出了所有显然未被选择的较易发生的替换,这要么是由于酶RT活性降低,要么是由于缺乏耐药性。这些关于耐药性要求的预测通过已发表的RT变异体突变数据得到了证实。我们还提出,在需要多个氨基酸变化以实现最佳适应性的情况下,突变类型的差异可以解释替换出现的顺序。与在接受治疗的患者中发现的变异体相比,组织培养中筛选出的耐药HIV-1变异体的突变模式存在差异。与体内情况不同,体外组织培养系统处理的群体规模相对较小,这可能会限制产生耐药突变的机会。事实上,对密码子变化的检查表明,体外培养系统更倾向于相对容易发生的核苷酸替换。这些结果表明,核苷酸替换模式可以提供有关RT耐药性的重要信息。